ZYME vs ARVN

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 15, 2026

ZYME

31.8
AI Score
VS
ARVN Wins

ARVN

38.2
AI Score

Investment Advisor Scores

ZYME

32score
Recommendation
SELL

ARVN

38score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric ZYME ARVN Winner
Revenue 7.00M 265.30M ARVN
Net Income -89.18M 111.80M ARVN
Net Margin -1274.4% 42.1% ARVN
Operating Income -89.30M 100.30M ARVN
ROE -111.0% 19.9% ARVN
ROA -22.5% 16.6% ARVN
Total Assets 396.96M 675.10M ARVN
Cash 179.41M 94.30M ZYME
Current Ratio 6.32 7.91 ARVN
Free Cash Flow -77.88M -119.00M ZYME

Relative Price Performance (Last 90 Days)

ZYME 1M: +24.0% · 3M: +14.2% ARVN 1M: +15.3% · 3M: +2.9%

Current Technical Phase

ZYME

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 72

RSI (14): 71.6 · Price: $28.67

ARVN

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (1.4% over 20 days), RSI 60

RSI (14): 60.1 · Price: $9.37

Fundamentals Snapshot

Metric ZYME ARVN
Market Cap
Forward P/E 24.4 -3.0
Trailing P/E 37.6
Revenue (TTM)
Revenue Growth -0.9% 10.1%
Gross Margin -2.5% 1.0%
Operating Margin -9.2% 0.7%
EPS -2.02 0.24
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, ARVN is currently the stronger investment candidate, winning 8 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.